Current status of and future prospects for the medical management of adenocarcinoma of the exocrine pancreas

Journal of Clinical Gastroenterology

Volumn 30, Issue 4, 2000, Pages 357-363

  Wiernik, Peter H ^a,b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b OLM Comprehensive Cancer Center   (United States)

Author keywords

Cancer treatment; Chemotherapy; Pancreatic cancer

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; ALPHA INTERFERON; ANTISENSE OLIGODEOXYNUCLEOTIDE; AZATHIOPRINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FLUTAMIDE; FOLINIC ACID; GEMCITABINE; HYDROXYUREA; IFOSFAMIDE; ISOTRETINOIN; LOXIGLUMIDE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; METHOTREXATE; MITOMYCIN C; PACLITAXEL; RALTITREXED; SPARFOSIC ACID; TAXANE DERIVATIVE; TEMOZOLOMIDE; TOPOTECAN; UFT;

ADVANCED CANCER; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; GENE THERAPY; HUMAN; MULTIMODALITY CANCER THERAPY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; REVIEW;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FLUOROURACIL; GENE THERAPY; HUMANS; PANCREATECTOMY; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT;

EID: 0034088445     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200006000-00003     Document Type: Review

References (79)

1. Janes RH Jr, Niederhuber JE, Chmiel JS, et al. National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer. Ann Surg 1996;223:261-72.
2. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997;226:248-57.
3. Mukaiya M, Hirata K, Satoh T, et al. Lack of survival benefit of extended lymph node dissection for ductal adenocarcinoma of the head of the pancreas: retrospective multi-institutional analysis in Japan. World J Surg 1998;22: 248-52.
4. Leach SD, Lee JE, Charnsangavej C, et al. Survival following pancreatico-duodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 1998;85:611-7.
5. Schuricht AL, Spitz F, Barbot D, Rosato F. Intraoperative radiotherapy in the combined-modality management of pancreatic cancer. Am Surg 1998;64: 1043-9.
6. Nishimura Y, Hosotani R, Shibamoto Y, et al. External and intraoperative radiotherapy for resectable and unresectable pancreatic cancer: analysis of survival rates and complications. Int J Radiat Oncol Biol Phys 1997;1:39-49.
7. Coquard R, Ayzac L, Gilly FN, et al. Intraoperative radiotherapy in resected pancreatic cancer: feasibility and results. Radiother Oncol 1997;44:271-5.
8. Hosotani R, Kogire M, Arii S, Nishimura Y, Hiraoka M, Imamura M. Results of pancreatectomy with radiation therapy for pancreatic cancer. Hepatogastroenterology 197;44:1528-35.
9. Pisters PW, Abbruzzese JL, Janjan NA, et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 1998;16: 3843-50.
10. Pendurthi TK, Hoffman JP, Ross E, Johnson DE, Eisenberg BL. Preoperative versus postoperative chemoradiation for patients with resected pancreatic adenocarcinoma. Am Surg 1998;64:686-92.
11. Jeekel J. Adjuvant or neoadjuvant therapy for pancreatic carcinoma? Digestion 1997;58:533-5.
12. Neoptolemos JP, Kerr DJ, Beger H, et al. ESPAC-1 trial progress report: the European randomized adjuvant study comparing radiochemotherapy, 6 months chemotherapy and combination therapy versus observation in pancreatic cancer. Digestion 1997;58:570-7.
13. Huguier M, Mason NP. Treatment of cancer of the exocrine pancreas. Am J Surg 1999;177:257-65.
14. Lygidakis NJ, Berberabe AE, Spentzouris N, et al. A prospective randomized study using adjuvant locoregional chemoimmunotherapy in combination with surgery for pancreatic carcinoma. Hepatogastroenterology 1998;45: 2376-81.
15. rd. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1998;16:317-23.
16. Poen JC, Collins HL, Niederhuber JE, et al. Chemo-radiotherapy for localized pancreatic cancer: increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion 5-fluorouracil. Int J Radiat Oncol Biol Phys 1998;40:93-9.
17. Todd KE, Gloor B, Lane JS, Isacoff WH, Reber HA. Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole. J Gastrointest Surg 1998;2:159-66.
18. Di Costanzo F, Tagliaventi M, Carlini P, et al. high-dose folinic acid and fluorouracil with or without ifosfamide is an inactive combination in advanced pancreatic cancer. A randomized phase II study of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Am J Clin Oncol 1996;19: 307-10.
19. Poorter RL, Bakker PJ, Huizing MT, et al. Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas. Ann Oncol 1995;6:1048-9.
20. Sporn JR, Buzaid AC, Slater D, Cohen N, Greenberg BR. Treatment of advanced pancreatic adenocarcinoma with 5-FU, leucovorin, interferon-alpha-2b, and cisplatin. Am J Clin Oncol 1997;20:81-3.
21. John WJ, Flett MQ. Continuous venous infusion 5-fluorouracil and interferon-alpha in pancreatic carcinoma. Am J Clin Oncol 1998;2:147-50.
22. Evans TR, Lofts FJ, Mansi JL, Glees JP, Dalgleish AG, Knight MJ. A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br J Cancer 1996;73:1260-4.
23. Andre T, Lotz JP, Bouleuc C, et al. Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma. Ann Oncol 1996;7:173-8.
24. Okusaka T, Okada S, Ishii H, et al. Clinical response to systemic combined chemotherapy with 5-fluorouracil and cisplatin (FP therapy) in patients with advanced pancreatic cancer. Jpn J Clin Oncol 1996;26:215-20.
25. Colleoni M, Nelli P, Vicario G, Pancheri F, Sgarbossa G, Manente P. Phase II study of oral L-leucovoin, 120-hour fluorouracil infusion and carboplatin in advanced pancreatic cancer. Tumori 1996;82:573-5.
26. Auerbach M, Wampler GL, Lokich JJ, Fryer D, Fryer JG, Ahlgren JD. Treatment of advanced pancreatic carcinoma with a combination of protracted infusional 5-fluorouracil and weekly carboplatin: a Mid-Atlantic Oncology Program Study. Ann Oncol 1997;8:439-44.
27. Rubin J, Gallagher JG, Schroeder G, et al. Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma. Cancer 1996;1:1888-91.
28. Gebbia V, Majello E, Testa A, et al. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of multicenter study of Southern Italy Oncology Group (G.O.I.M.). Cancer 1996;78:1300-7.
29. Tsavaris T, Tentas K, Tzivras M, et al. Combined epirubicin, 5-fluorouracil and folinic acid vs no treatment for patients with advanced pancreatic cancer: a prospective comparative study. J Chemother 1998;10:331-7.
30. Maiello E, Gebbia V, Giuliani F, et al. A phase II trial of etoposide, folinic acid, fluorouracil and epirubicin in advanced pancreatic carcinoma. Clin Ter 1998;149:351-5.
31. Raderer M, Kornek, GV, Hejna MH, et al. Treatment of advanced pancreatic cancer with epirubicin, 5-fluorouracil and 1-leucovorin: a phase II study. Ann Oncol 1997;8:797-9.
32. Harstick A, Kohne CH, Hiddemann W, et al. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonoacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma. Ann Oncol 1997;8:917-8.
33. Mani S, Kugler JW, Sciortino DF, et al. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study. Ann Oncol 1998;9:1035-7.
34. Thomas CR Jr, Weiden PL, Traverso LW, Thompson T. Concomitant intraarterial cisplatin, intravenous 5-fluorouracil, and split-course radiation therapy for locally advanced unresectable pancreatic adenocarcinoma: a phase II study of the Puget Sound Oncology Consortium (PSOC-703). Am J Clin Oncol 1997;20:161-5.
35. Ishii H, Okada S, Tokuuye K, et al. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 1997;15:1516-20.
36. Whitehead RP, Jacobson J, Brown TD, Taylor SA, Weiss GR, Macdonald JS. Phase II trial of paclitaxel and granulocyte colony-stimulating factor inpatients with pancreatic carcinoma: a Southwest Oncology Group study. J Clin Oncol 1997;15:2414-9.
37. Safran H, Cioffi W, Iannitti D, Mega A, Akerman P. Paclitaxel and concurrent radiation for locally advanced pancreatic carcinoma. Front Biosci 1998; 3:E204-6.
38. Safran H, Akerman P, Cioffi W, et al. Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction. Semin Radiat Oncol 1999;9:53:7.
39. Rougier P. Docetaxel delivers new management opportunities for gastrointestinal carcinomas. Anticancer Drugs 1995;4:25-29.
40. Nobel S, Goa KL. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 1997; 54:447-72.
41. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347-53.
42. rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
43. Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 1997; 33:S18-22.
44. Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 1999; 15:1261-8.
45. Carmichael J. Clinical response benefit in patients with advanced pancreatic cancer. Role of gemcitabine. Digestion 1997;58:503-7.
46. Von Hoff DD, Goodwin AL, Garcia L. Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team. Br J Cancer 1998;3:9-13.
47. Van Moorsel CJ, Veerman G, Bergman AM, et al. Combination chemotherapy with gemcitabine. Semin Oncol 1997;24:S7-17-S7-23.
48. Pollera CF, Ceribelli A, Crecco M, Oliva C, Calabresi F. Prolonged infusion gemcitabine: a clinical phase I study at low-(300 mg/m2) and high-dose (875 mg/m2) levels. Invest New Drugs 1997;15:115-21.
49. Brand R, Capadano M, Tempero M. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 1997;15:331-41.
50. Stevenson JP, Scher RM, Kosierowski R, et al. Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. Eur J Cancer 1998;34:1358-62.
51. Scher RM, Kosierowski R, Lusch C, et al. Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Invest New Drugs 1996;13:3437-54.
52. O'Reilly S, Donehower RC, Rowinsky EK, Ord S, Grochow LB. A phase II trial of topotecan in patients with previously untreated pancreatic cancer. Anticancer Drugs 1996;7:410-4.
53. Pazdur R, Meropol NJ, Casper ES, et al. Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer. Invest New Drugs 1996;13: 355-8.
54. Zalupski MM, Shields AF, Philip PA, et al. Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma. Invest New Drugs 1998;16: 93-6.
55. Moore MJ, Feld R, Hedley D, Oza A, Siu LL. A phase II study of temozolomide in advanced untreated pancreatic cancer. Invest New Drugs 1998;16: 77-9.
56. Militello C, Sperti C, Di Prima F, Pedrazzoli S. Clinical evaluation and safety of loxiglumide (CCK-A receptor antagonist) in nonresectable pancreatic cancer patients. Italian Pancreatic Cancer Study Group. Pancreas 1997;14: 222-8.
57. Sharma JJ, Razvillas B, Stephens CE, Hilsenbeck SG, Sharma A, Rothenberg ML. Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer. Invest New Drugs 1997;15:361-4.
58. Greenway BA. Effect of flutamide on survival in patients with pancreatic cancer: results of a prospective, randomized, double blind, placebo controlled trial. BMJ 1998;316:1935-8.
59. Miller KD, Loehrer PJ, Gonin R, et al. A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma. Invest New Drugs 1996;14:207-12.
60. Moore DF Jr, Pazdur R, Sugarman S, et al. Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha combination therapy for advanced pancreat adenocarcinoma. Am J Clin Oncol 1995;18:525-7.
61. Brembeck FH, Schoppmeyer K, Leupold U, et al. A phase II pilot trial of I3-cis retinoic acid and interferon-alpha in patients with advanced pancreatic carcinoma. Cancer 1998;83:2317-23.
62. Stehlin JS, Giovanella BC, Natelson EA, et al. A sudy of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. Int J Oncol 1999; 14:821-1.
63. Rosemurgy A, Harris J, Langleben A, Casper E, Goode S, Rasmussen H. Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am J Clin Oncol 1999;22:247-52.
64. Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus an batimastat and marimastat. Pharmacol Ther 1997;75:69-75.
65. Bramhall SR. The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application. Int J Pancreatol 1997;21:1-12.
66. Bramhall SR. Stromal degradation by the malignant epithelium in pancreatic cancer and the therapeutic potential of proteolytic inhibition. J Hepatobiliary Pancreat Surg 1998;5:392-401.
67. Smith JP, Verderame MF, Zagon IS. Antisense oligonucleotides to gastrin inhibit growth of human pancreatic cancer. Cancer Lett 1999;135:107-12.
68. Fiedler A, Knorre C, Franke Y, et al. Growth inhibition of pancreatic tumor cells by modified antisense oligodeoxynucleotides. Langenbecks Arch Surg 1998;383:269-75.
69. Freeman JW, Strodel WE, McGrath PC. Efficacy of p120 antisense-mediated therapy for pancreatic cancer. J Gastrointest Surg 1997;1:454-60.
70. Pearson AS, Vouvet M, Evans DB, Roth JA. Gene therapy and pancreatic cancer. Front Biosc 1998;1:E230-7.
71. Bouvet M, Bold RJ, Lee J, et al. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Ann Surg Oncol 1998;5:681-8.
72. Hwang RF, Gordon EM, Anderson WF, Parekh D. Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene. Surgery 1998;124:143-50.
73. Grossmann, A, Rameken M, Klapdor R. Active-specific immunotherapy of pancreatic carcinoma: usefulness of human pancreatic carcinomas in preparing autologous tumor vaccines. Anticancer Res 1997;17:3117-9.
74. Friess H, Lu Z, Andren-Sandberg A, et al. Moderate activation of the apoptosis inhibitor bel-xL worsens the prognosis in pancreatic cancer. Ann Surg 1998;228:780-7.
75. McDade TP, Perugini RA, Vittimberga FJ Jr, Carrigan RC, Callery MP. Salicylates inhibit NF-kappaB activation and enhance TNF-alpha-induced apoptosis in human pancreatic cancer cells. J Surg Res 1999;83:56-61.
76. Fujimoto K, Hosotani R, Doi R, et al. Induction of cell-cycle arrest and apoptosis by a novel retinobenzoic-acid derivative, TAC-101, in human pancreatic-cancer cells. Int J Cancer 1999;81:637-44.
77. Li Y, Singh B, Ali N, Sarkar FH. Induction of growth inhibition and apoptosis in pancreatic cancer cells by auristatin-PE and gemcitabine. Int J Mol Med 1999;3:647-53.
78. Ikeda N, Adachi M, Taki T, et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 1999;79:1553-63.
79. Kleeff, J, Ishiwata T, Kumbasar A, et al. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest 1998;102:1662-73.